Searle Reliance On Celebrex Increases After GP IIb/IIIa Program Discontinued
Executive Summary
Searle's dependence on the launch of its arthritis pain reliever Celebrex has increased after the company discontinued its glycoprotein IIb/IIIa receptor antagonist development program.